Guideline to Multiple Myeloma Treatment Strategies
Pp. 73-87 (15)
Jonathan L. Kaufmann,
Jacob P. Laubach,
Paul G. Richardson,
Kenneth C. Anderson
Multiple Myeloma (MM) is a clonal plasma cell malignancy with a highly heterogeneous
genetic background, characterized by bone marrow (BM) plasmacytosis, production of monoclonal
proteins, osteolytic bone lesions, renal disease, anemia, hypercalcemia, and immunodeficiency. The
inclusion of thalidomide, bortezomib, and lenalidomide into conventional cytotoxic and transplantation
regimens, first in relapsed and refractory and now also in newly diagnosed MM, has fundamentally
changed treatment in MM during the last decade and steadily improved MM patient outcome.
Clinical features, monoclonal gammopathy of unknown significance (MGUS), smoldering
multiple myeloma (SMM), CRAB, staging (Durie-Salmon, International Staging System), upfront therapy,
autologous stem cell transplantation (ASCT), maintenance therapy, salvage therapy, bone disease.